Vectorite Biomedical Inc. (TPEX:4170)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
12.45
+0.25 (2.05%)
Sep 15, 2026, 2:00 PM CST

Vectorite Biomedical Revenue

Vectorite Biomedical had revenue of 27.13M TWD in the half year ending June 30, 2026, with 14.95% growth. This brings the company's revenue in the last twelve months to 54.81M, down -19.28% year-over-year. In the year 2025, Vectorite Biomedical had annual revenue of 61.41M with 6.29% growth.

Revenue (ttm)
54.81M
Revenue Growth
-19.28%
P/S Ratio
1.40
Revenue / Employee
n/a
Employees
n/a
Market Cap
76.56M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202561.41M3.64M6.29%
Dec 31, 202457.77M1.92M3.43%
Dec 31, 202355.85M12.94M30.15%
Dec 31, 202242.91M14.14M49.16%
Dec 31, 202128.77M4.23M17.22%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
BioLASCO Taiwan258.04M
RBC Bioscience220.60M
Visgeneer170.72M
Lukas Biomedical170.01M
Feng Chi Biotech156.99M
Enimmune53.45M
Neith31.84M
SynCore Biotechnology Co.,Ltd26.24M
Revenue Rankings